Our Science Sironax Explore the critical role of nampt in energy homeostasis and the therapeutic potential of nampt activator in muscular degenerative diseases. From platform selection to assay development and advanced analysis, our dedicated team remains steadfast in delivering cutting edge solutions and services for our clients.
Our Science Sironax If novartis decides to buy the platform, the swiss pharma will have full global rights to the sironax science, giving the biotech the chance to make up to $175 million in upfront and near term. Sironax' lead ripk1 drug, sir0365, has completed two phase 1b studies including one looking at its potential as a treatment for severe hyperinflammation associated with covid 19 infections, while. Sironax is a clinical stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunological, metabolic, and rare diseases. Through the collaboration, x chem will screen its unique dna encoded libraries against difficult to drug targets implicated in neurodegenerative disease to discover hits. in turn, sironax will prosecute these hits into transformational medicines for degenerative disease.
Our Pipeline Sironax Sironax is a clinical stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunological, metabolic, and rare diseases. Through the collaboration, x chem will screen its unique dna encoded libraries against difficult to drug targets implicated in neurodegenerative disease to discover hits. in turn, sironax will prosecute these hits into transformational medicines for degenerative disease. About sironax sironax is a clinical stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunological, metabolic and rare diseases. Sironax was honored at an awards gala in boston on sept. 18, 2025. “we are thrilled to have received this distinguished recognition from endpoint news as a reflection of our scientific innovation to date,” said dr. shefali agarwal, president and ceo of sironax. Sironax is an emerging leader in the discovery and development of transformational therapies that address the root cause of age related degenerative disease. today, the majority of treatments for these diseases are palliative, with a focus on alleviating symptoms alone. Sironax is a clinical stage biotechnology company dedicated to the discovery and global development of novel treatments for age related degenerative diseases.
Our Pipeline Sironax About sironax sironax is a clinical stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunological, metabolic and rare diseases. Sironax was honored at an awards gala in boston on sept. 18, 2025. “we are thrilled to have received this distinguished recognition from endpoint news as a reflection of our scientific innovation to date,” said dr. shefali agarwal, president and ceo of sironax. Sironax is an emerging leader in the discovery and development of transformational therapies that address the root cause of age related degenerative disease. today, the majority of treatments for these diseases are palliative, with a focus on alleviating symptoms alone. Sironax is a clinical stage biotechnology company dedicated to the discovery and global development of novel treatments for age related degenerative diseases.
Contact Us Sironax Sironax is an emerging leader in the discovery and development of transformational therapies that address the root cause of age related degenerative disease. today, the majority of treatments for these diseases are palliative, with a focus on alleviating symptoms alone. Sironax is a clinical stage biotechnology company dedicated to the discovery and global development of novel treatments for age related degenerative diseases.
Comments are closed.